Retinal fluorescence lifetime imaging ophthalmoscopy measures depend on the severity of Alzheimer's disease

Acta Ophthalmologica

Volumn 93, Issue 4, 2015, Pages e241-e247

  Jentsch, Susanne ^a   Schweitzer, Dietrich ^a   Schmidtke, Kai Uwe ^a   Peters, Sven ^a   Dawczynski, Jens ^b   Bär, Karl Jürgen ^a   Hammer, Martin ^a,c  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Alzheimer's disease; amyloid ; fluorescence lifetime imaging ophthalmoscopy; fundus autofluorescence; nerve fibre layer; tau protein

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; PHOSPHOPROTEIN; PROTEIN TAU181; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; MAPT PROTEIN, HUMAN;

ACTION POTENTIAL AMPLITUDE; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOFLUORESCENCE IMAGING; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FLUORESCENCE DECAY ANALYSIS; FLUORESCENCE LIFETIME IMAGING OPHTHALMOSCOPY; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MACULAR THICKNESS; MALE; MINI MENTAL STATE EXAMINATION; OPHTHALMOSCOPY; OPTIC DISK; OPTICAL COHERENCE TOMOGRAPHY; PILOT STUDY; PRIORITY JOURNAL; RETINAL NERVE FIBER LAYER THICKNESS; SCANNING LASER OPHTHALMOSCOPY; TIME CORRELATED SINGLE PHOTON COUNTING; CEREBROSPINAL FLUID; CYTOLOGY; FLUORESCENCE IMAGING; INTELLIGENCE TEST; NERVE FIBER; PATHOPHYSIOLOGY; RETINA GANGLION CELL; RETINAL DISEASES; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; FEMALE; HUMANS; INTELLIGENCE TESTS; MALE; NERVE FIBERS; OPHTHALMOSCOPY; OPTICAL IMAGING; RETINAL DISEASES; RETINAL GANGLION CELLS; SEVERITY OF ILLNESS INDEX; TAU PROTEINS;

EID: 84929511424     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.12609     Document Type: Article

References (43)

1. Andersson-Engels S, Johansson J, Svanberg K, &, Svanberg S, (1991): Fluorescence imaging and point measurements of tissue: applications to the demarcation of malignant tumors and atherosclerotic lesions from normal tissue. Photochem Photobiol 53: 807-814.
2. Becker W, (2012): Fluorescence lifetime imaging - techniques and applications. J Microsc 247: 119-136.
3. Berezin MY, &, Achilefu S, (2010): Fluorescence lifetime measurements and biological imaging. Chem Rev 110: 2641-2684.
4. Bird DK, Yan L, Vrotsos KM, Eliceiri KW, Vaughan EM, Keely PJ, White JG, &, Ramanujam N, (2005): Metabolic mapping of MCF10A human breast cells via multiphoton fluorescence lifetime imaging of the coenzyme NADH. Cancer Res 65: 8766-8773.
5. Boettner EA, &, Wolter JR, (1962): Transmission of the ocular media. Investig Ophthalmol 1: 776-783.
6. Chorvat D, &, Chorvatova A, (2009): Multi-wavelength fluorescence lifetime spectroscopy: a new approach to the study of endogenous fluorescence in living cells and tissues. Laser Phys Lett 6: 175-193.
7. Cubeddu R, Docchio F, Ramponi R, &, Boulton M, (1990): Time-resolved fluorescence spectroscopy of the retinal-pigment epithelium-age-related studies. IEEE J Quantum Electron 26: 2218-2225.
8. Dowling K, Dayel MJ, Lever MJ, French PM, Hares JD, &, Dymoke-Bradshaw AK, (1998): Fluorescence lifetime imaging with picosecond resolution for biomedical applications. Opt Lett 23: 810-812.
9. Feher J, Kovacs I, Artico M, Cavallotti C, Papale A, &, Balacco Gabrieli C, (2006): Mitochondrial alterations of retinal pigment epithelium in age-related macular degeneration. Neurobiol Aging 27: 983-993.
10. Folstein MF, Folstein SE, &, McHugh PR, (1975): "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
11. Gupta N, Fong J, Ang LC, &, Yucel YH, (2008): Retinal tau pathology in human glaucomas. Can J Ophthalmol 43: 53-60.
12. Guze SB, (1995): Diagnostic and statistical manual of mental disorders, 4th ed. (DSM-IV). Am J Psychiatry 152: 1228.
13. Heikal AA, (2010): Intracellular coenzymes as natural biomarkers for metabolic activities and mitochondrial anomalies. Biomark Med 4: 241-263.
14. Ibach B, Binder H, Dragon M, Poljansky S, Haen E, Schmitz E, Koch H, Putzhammer A, Kluenemann H, Wieland W, &, Hajak G, (2006): Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample. Neurobiol Aging 27: 1202-1211.
15. Iseri PK, Altinas O, Tokay T, &, Yuksel N, (2006): Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuroophthalmol 26: 18-24.
16. Jaffe GJ, &, Caprioli J, (2004): Optical coherence tomography to detect and manage retinal disease and glaucoma. Am J Ophthalmol 137: 156-169.
17. Kesler A, Vakhapova V, Korczyn AD, Naftaliev E, &, Neudorfer M, (2011): Retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Clin Neurol Neurosurg 113: 523-526.
18. Kirbas S, Turkyilmaz K, Anlar O, Tufekci A, &, Durmus M, (2013): Retinal nerve fiber layer thickness in patients with Alzheimer disease. J Neuroophthalmol 3: 58-61.
19. Konig K, (2008): Clinical multiphoton tomography. J Biophotonics 1: 13-23.
20. Lakowicz JR, (2006): Principles of fluorescence spectroscopy. New York, NY: Springer.
21. Lakowicz JR, Szmacinski H, Nowaczyk K, &, Johnson ML, (1992): Fluorescence lifetime imaging of free and protein-bound NADH. Proc Natl Acad Sci USA 89: 1271-1275.
22. Leger F, Fernagut PO, Canron MH, Leoni S, Vital C, Tison F, Bezard E, &, Vital A, (2011): Protein aggregation in the aging retina. J Neuropathol Exp Neurol 70: 63-68.
23. Loffler KU, Edward DP, &, Tso MO, (1995): Immunoreactivity against tau, amyloid precursor protein, and beta-amyloid in the human retina. Invest Ophthalmol Vis Sci 36: 24-31.
24. Lu Y, Li Z, Zhang X, Ming B, Jia J, Wang R, &, Ma D, (2010): Retinal nerve fiber layer structure abnormalities in early Alzheimer's disease: evidence in optical coherence tomography. Neurosci Lett 480: 69-72.
25. McKhann G, Drachman D, Folstein M, Katzman R, Price D, &, Stadlan EM, (1984): Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944.
26. Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, Thorpe SR, Baynes JW, Gans RO, &, Smit AJ, (2004): Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 47: 1324-1330.
27. Morris JC, (1993): The clinical dementia rating (CDR): current version and scoring rules. Neurology 43: 2412-2414.
28. Moschos MM, Markopoulos I, Chatziralli I, Rouvas A, Papageorgiou SG, Ladas I, &, Vassilopoulos D, (2012): Structural and functional impairment of the retina and optic nerve in Alzheimer's disease. Curr Alzheimer Res 9: 782-788.
29. Ning A, Cui J, To E, Ashe KH, &, Matsubara J, (2008): Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease. Invest Ophthalmol Vis Sci 49: 5136-5143.
30. Oswald WD, &, Fleischmann UM, (1985): Psychometrics in aging and dementia: advances in geropsychological assessments. Arch Gerontol Geriatr 4: 299-309.
31. Paquet C, Boissonnot M, Roger F, Dighiero P, Gil R, &, Hugon J, (2007): Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 420: 97-99.
32. Perez SE, Lumayag S, Kovacs B, Mufson EJ, &, Xu S, (2009): Beta-amyloid deposition and functional impairment in the retina of the APPswe/PS1DeltaE9 transgenic mouse model of Alzheimer's disease. Invest Ophthalmol Vis Sci 50: 793-800.
33. Peters S, Hammer M, &, Schweitzer D, (2011): Two-photon excited fluorescence microscopy application for ex vivo investigation of ocular fundus samples. In:, So P, &, Beaurepaire E, (eds.) European Conference on Biomedical Optics (ECBO). Munich, Germany: Optical Society of America: 808605.
34. Petersen RC, (2007): Mild cognitive impairment: current research and clinical implications. Semin Neurol 27: 22-31.
35. Reus NJ, &, Lemij HG, (2004): Diagnostic accuracy of the GDx VCC for glaucoma. Ophthalmology 111: 1860-1865.
36. Schweitzer D, (2009): Quantifying fundus autofluorescence. In:, Lois N, Forrester JV, (eds) Fundus autofluorescence. Philadelphia, PA: Lippincott Williams & Wilkins 78-98.
37. Schweitzer D, (2010): Metabolic mapping. In:, Holz F, (ed.) Medical retina: focus on retinal imaging. Berlin, Heidelberg: Springer Berlin Heidelberg 107-124.
38. Schweitzer D, Gaillard ER, Dillon J, Mullins RF, Russell S, Hoffmann B, Peters S, Hammer M, &, Biskup C, (2012): Time-resolved autofluorescence imaging of human donor retina tissue from donors with significant extramacular drusen. Invest Ophthalmol Vis Sci 53: 3376-3386.
39. Schweitzer D, Klemm M, Quick S, Deutsch L, Jentsch S, Hammer M, Dawczynski J, Kloos CH, &, Mueller UA, (2011): Detection of early metabolic alterations in the ocular fundus of diabetic patients by time-resolved autofluorescence of endogenous fluorophores. In:, Ramanujam N, &, Popp J, (eds.). Proc. SPIE 8087, Clinical and Biomedical Spectroscopy and Imaging II, 80871G (10 June 2011) Optical society of America. 80871G.
40. Schweitzer D, Quick S, Schenke S, Klemm M, Gehlert S, Hammer M, Jentsch S, &, Fischer J, (2009): Comparison of parameters of time-resolved autofluorescence between healthy subjects and patients suffering from early AMD. Ophthalmologe 106: 714-722.
41. Schweitzer D, Schenke S, Hammer M, Schweitzer F, Jentsch S, Birckner E, Becker W, &, Bergmann A, (2007): Towards metabolic mapping of the human retina. Microsc Res Tech 70: 410-419.
42. Sparrow JR, Parish CA, Hashimoto M, &, Nakanishi K, (1999): A2E, a lipofuscin fluorophore, in human retinal pigmented epithelial cells in culture. Invest Ophthalmol Vis Sci 40: 2988-2995.
43. Welge V, Fiege O, Lewczuk P, Mollenhauer B, Esselmann H, Klafki HW, Wolf S, Trenkwalder C, Otto M, Kornhuber J, Wiltfang J, &, Bibl M, (2009): Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm 116: 203-212.